Meloxicam Use in Patients with Renal Impairment

Guideline-Based Contraindications

• The American College of Cardiology and American Heart Association recommend avoiding NSAIDs, including meloxicam, in patients with heart failure or cardiovascular disease, as they can adversely affect clinical status in these populations, with a Class III: Harm recommendation 1
• Patients should be counseled to avoid NSAIDs when taking aldosterone receptor antagonists or other RAAS inhibitors, as NSAIDs increase the risk of hyperkalemia and can precipitate acute kidney injury, according to the American Heart Association 2, 3

Risk Stratification Algorithm

• High-risk patients, including those with heart failure, should avoid meloxicam entirely, as recommended by the American Heart Association 1
• The American Heart Association also recommends avoiding meloxicam in patients with concurrent use of ACE inhibitors, ARBs, or aldosterone antagonists 2, 3

Monitoring and Alternatives

• The American Heart Association recommends monitoring renal function within 1 week of initiation and then monthly for 3 months in moderate-risk patients with eGFR 30-60 3
• The American College of Physicians recommends using acetaminophen as first-line for mild-moderate pain in patients with eGFR 53, with no renal dose adjustment needed, as stated in the Mayo Clinic Proceedings 4
• If opioids are required, the Mayo Clinic Proceedings recommend avoiding tramadol and using caution with hydrocodone/oxycodone, while fentanyl has no active metabolites and is preferred for severe renal impairment 4, 5